Celltrion, Hospira plot Aussie rollout of Remicade biosim; Sun Pharma quarter suffers on U.S. slowdown, Ranbaxy;

@FiercePharma: Real-time data can put slow drug launches into the fast lane, researcher says. More from FiercePharmaMarketing | Follow @FiercePharma

@EricPFierce: GSK stops production at North Carolina plant after Legionella bacteria found in cooling tower. News | Follow @EricPFierce

@CarlyHFierce: Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi. FiercePharmaMarketing story | Follow @CarlyHFierce

> Biosimilars maker Celltrion won Australian approval to sell its knockoff version of the anti-inflammatory blockbuster Remicade; partner Hospira ($HSP), soon to be part of Pfizer ($PFE), will take on marketing duties there. Report

> A slowdown in U.S. sales and the integration of Ranbaxy Laboratories took their toll on Sun Pharma's quarterly results, with profits falling as expected. Report

> India's Zydus Cadila said its quarterly net profit increased by almost half, thanks to a sales leap in the U.S. of 37%. Release

> Allergan ($AGN) confirmed that it's challenging Merck & Co.'s ($MRK) patent protection on the antifungal Noxafil and said it may be the first-to-file generics company for that drug. Release

> Britain's competition watchdog ordered Reckitt Benckiser to license out its K-Y brand in the region for 8 years to combat worries about its purchasing the product line from Johnson & Johnson ($JNJ). Report

> Me-too drugs may be due for an image overhaul now that competitive rivalries are helping bring down prices in some areas. Report

> India-based Claris Lifesciences won FDA approval to resume supplying its furosemide injection to the U.S. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Rehabilitation startup rolls out new muscle therapy device for leg paralysis. Story | Follow @FierceMedDev

@VarunSaxena2: Study: Device industry suffers from first-mover disadvantage due to FDA regs. Article | Follow @VarunSaxena2

@EmilyWFierce: UPDATED: Kim Kardashian Instagram post lands Duchesnay in FDA hot water. More from FiercePharmaManufacturing | Follow @EmilyWFierce

> New York startup trots out video-game like screening device for Alzheimer's. Story

> Helius enters clinical trial of its PoNS brain stimulation device to treat traumatic brain injury. More

> Wearable pain relief device set to hit store shelves due to distribution alliance. Report

Biotech News

@FierceBiotech: We're looking for 2015's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: What does Google's corporate shuffle mean for its biotech ambitions? Story | Follow @JohnCFierce

@DamianFierce: A wonderfully stern FDA official parses Kim Kardashian's Instagram. Warning letter | Follow @DamianFierce

> Sickle cell biotech GBT banks $120M in an above-range IPO. Article

> Post-Sarepta, Art Krieg gets $20M to take a shot at an immuno-oncology Checkmate. Story

> Nearing the brink, Eleven Bio bets it all on another PhIII eye study. More

Biotech Research News

> Vitamin B3 pathway may lead to new obesity drugs. Item

> MGH study pinpoints a genetic trigger for heart valve disorder. Report

> UBC team stakes a claim on a newly discovered 'obesity gene.' More

> Overstimulating oncogene family SRC shows promise against cancer. Story

> TSRI researchers say enzyme may work as an anti-smoking treatment. Article

Diagnostics News

> VisionGate sets sights on FDA approval for noninvasive lung cancer Dx. Editor's corner

> Biocept partners with UC Irvine on liquid biopsy research. News

> Response Genetics throws in towel, sells out to Cancer Genetics for $14M. More

> Roche selects Hawaii's Diagnostic Laboratory Services for molecular diagnostics project. Report

> Invitae dials up testing guidance amid positive Q2 numbers. Article

Pharma Marketing News

> Legionnaires' discovery prompts GlaxoSmithKline to idle NC plant. Item

> Real-time data can put slow drug launches into the fast lane, researcher says. Report

> Abbott, Novartis tap into #ILookLikeAnEngineer social media movement. More

> Kim Kardashian Instagram post lands Duchesnay in FDA hot water. Story

> Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi. Article

And Finally ... A Winnipeg, Canada, pharmacy was charged with smuggling bad cancer drugs to U.S. customers. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.